Nivolumab Improves Survival in Refractory HNSCC
Patients with platinum-refractory, recurrent head and neck squamous cell carcinoma (HNSCC) derive a significant overall survival (OS) benefit from treatment with the checkpoint inhibitor nivolumab relative to conventional alternatives, according to results of a Phase III trial.

Nivolumab (Opdivo, Bristol-Myers Squibb) “doubled the time to deterioration for most functional domains, prolonging the time that patients were without symptoms,” reported Kevin Harrington, MBBS, the joint head of the Division of Radiotherapy at Royal Marsden Hospital’s Institute of Cancer Research, in London. The results of the trial, called CheckMate 141, were presented at the European Society for Medical Oncology (ESMO) 2016 Congress (abstract LBA4_PR) and simultaneously published in The New England Journal of Medicine...

http://www.clinicaloncology.com/Head-Neck-Cancers/Article/12-16/Nivolumab-Improves-Survival-in-Refractory-HNSCC/38861
Like
Comment
Share